Labcorp (NYSE:LH), a global leader in innovative laboratory services, has announced the launch of the Labcorp Fentanyl Urine Visual Test.
The diagnostic tool represents a significant advancement in the domestic healthcare landscape as the first FDA-cleared rapid fentanyl urine test of its kind to be manufactured within the United States.
Designed for use by CLIA-certified professionals, the test addresses an urgent need for efficient, accessible screening tools in clinical and emergency settings.
The diagnostic delivers visual results in approximately 10 minutes and is engineered to detect norfentanyl, a primary metabolite of fentanyl.
This allows for an expanded detection window of up to 48 hours following exposure.
While the test provides critical immediate data, Labcorp specified that results are intended as preliminary screenings and should be validated through confirmed laboratory methods for definitive clinical or legal conclusions.